Avid Bioservices Stock Forecast, Price & News

Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

Is Avid Bioservices a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices or view top-rated stocks.

How has Avid Bioservices' stock been impacted by Coronavirus (COVID-19)?

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CDMO shares have increased by 586.7% and is now trading at $30.97.
View which stocks have been most impacted by COVID-19.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Tuesday, December 7th 2021.
View our earnings forecast for Avid Bioservices.

How can I listen to Avid Bioservices' earnings call?

Avid Bioservices will be holding an earnings conference call on Tuesday, December 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) released its quarterly earnings results on Tuesday, September, 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.04 by $0.06. The biopharmaceutical company earned $30.75 million during the quarter, compared to analysts' expectations of $25 million. Avid Bioservices had a net margin of 12.63% and a trailing twelve-month return on equity of 19.89%. During the same period in the previous year, the firm posted $0.06 EPS.
View Avid Bioservices' earnings history.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Shares of Avid Bioservices reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2022 earnings guidance on Thursday, October, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $115 million-$117 million, compared to the consensus revenue estimate of $115.83 million.

What price target have analysts set for CDMO?

3 brokerages have issued twelve-month price targets for Avid Bioservices' stock. Their forecasts range from $27.00 to $29.00. On average, they expect Avid Bioservices' share price to reach $28.00 in the next twelve months. This suggests that the stock has a possible downside of 9.6%.
View analysts' price targets for Avid Bioservices or view top-rated stocks among Wall Street analysts.

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the following people:

• Nicholas S. Green, President, Chief Executive Officer & Director
• Richard A. Richieri, Chief Operating Officer
• Daniel Ryan Hart, Chief Financial Officer (LinkedIn Profile)
• Nick Ferguson, Executive Director-Information Technology
• Mark R. Ziebell, Secretary, Vice President & General Counsel (LinkedIn Profile)

What is Roger Lias' approval rating as Avid Bioservices' CEO?

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Avid Bioservices' key competitors?

Some companies that are related to Avid Bioservices include Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Biohaven Pharmaceutical (BHVN), Arrowhead Pharmaceuticals (ARWR), Grifols (GRFS), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Zai Lab (ZLAB), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Mawson Infrastructure Group (WIZP) and Perrigo (PRGO).
View all of CDMO's competitors.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.15%), AltraVue Capital LLC (4.02%), Invesco Ltd. (1.96%), Jennison Associates LLC (1.72%), Geode Capital Management LLC (1.63%) and Dimensional Fund Advisors LP (1.44%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Daniel Ryan Hart, Mark R Bamforth, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends for Avid Bioservices.

Which major investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Pier Capital LLC, Cinctive Capital Management LP, Morgan Stanley, Renaissance Technologies LLC, Squarepoint Ops LLC, Kornitzer Capital Management Inc. KS, and Invesco Ltd.. Company insiders that have sold Avid Bioservices company stock in the last year include Daniel R Hart, Mark R Ziebell, Nicholas Stewart Green, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices or view top insider-selling stocks.

Which major investors are buying Avid Bioservices stock?

CDMO stock was acquired by a variety of institutional investors in the last quarter, including AltraVue Capital LLC, Jennison Associates LLC, Millennium Management LLC, CastleArk Alternatives LLC, Phocas Financial Corp., Dimensional Fund Advisors LP, Peregrine Capital Management LLC, and Assenagon Asset Management S.A.. Company insiders that have bought Avid Bioservices stock in the last two years include Daniel Ryan Hart, Mark R Bamforth, Patrick D Walsh, and Richard B Hancock.
View insider buying and selling activity for Avid Bioservices or or view top insider-buying stocks.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $30.97.

How much money does Avid Bioservices make?

Avid Bioservices has a market capitalization of $1.90 billion and generates $95.87 million in revenue each year. The biopharmaceutical company earns $11.21 million in net income (profit) each year or $0.08 on an earnings per share basis.

How many employees does Avid Bioservices have?

Avid Bioservices employs 255 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is www.avidbio.com.

Where are Avid Bioservices' headquarters?

Avid Bioservices is headquartered at 2642 Michelle Drive Suite 200, TUSTIN CA, 92780.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at [email protected], or via fax at 714-838-5817.